Atp-sensitive potassium channel modulators and cardiac arrhythmias: An update

Research output: Contribution to journalArticle

4 Citations (Scopus)


Ischemia and heart failure-related cardiac arrhythmias, both atrial (e.g., atrial fibrillation) and ventricular (e.g., malignant tachyarrhythmias) represent a leading cause of morbidity and mortality worldwide. Despite the progress made in the last decade in understanding their pathophysiological mechanisms there is still an unmet need for safer and more efficacious pharmacological treatment, especially when considering the drawbacks and complications of implantable devices. Cardiac ATP-sensitive potassium channels located in the sarcolemmal membrane (sarcKATP) and the inner mitochondrial membrane (mitoKATP) have emerged as crucial controllers of several key cellular functions. In the past three decades a tremendous amount of research led to their structural and functional characterization unveiling both a protective role in cardiac adaptive responses to metabolic stress and a seemingly paradoxical role in promoting as well as protecting against a trial and ventricular arrhythmias. On the other hand, several KATP inhibitors have emerged as potential ischemia selective antiarrhythmic drugs. In this respect, cardioselective, chamber specific and combined sarcKATP and mito KATP modulators currently represent a promising field for drug development.

Original languageEnglish
Pages (from-to)1091-1102
Number of pages12
JournalCurrent pharmaceutical design
Issue number8
Publication statusPublished - Jan 1 2015


  • Cardiac arrhythmias
  • Pharmacological modulators
  • Sarcolemmal and Mitochondrial ATP-Sensitive Potassium Channels

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Atp-sensitive potassium channel modulators and cardiac arrhythmias: An update'. Together they form a unique fingerprint.

  • Cite this